Arcus Biosciences Q4 revenue falls, net loss widens

Arcus Biosciences

25/02/2026 22:00

Overview

Biopharmaceutical firm's Q4 revenue fell to $33 mln from $36 mln a year ago

Net loss widened to $106 mln from $93 mln

Company holds $1 bln in cash, ensuring funding until 2028

Outlook

Arcus plans Phase 3 study for casdatifan in 1L metastatic setting by end of 2026

Company expects at least two casdatifan data readouts in 2026

Arcus to advance inflammation program into clinical development in 2026

Result Drivers

R&D EXPENSES - Increased to $121 mln from $111 mln, primarily attributable to higher late-stage development costs

Company press release: ID:nBw8VK8qPa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$106 mln
Q4 Operating Expenses
$147 mln
Q4 Operating Income
-$114 mln
Q4 Pretax Profit
-$106 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arcus Biosciences Inc is $31.00, about 53.5% above its February 24 closing price of $20.19

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)